This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract has a firm fixed price, with a ceiling value of $88,842.60, and was awarded on September 8, 2017 with a completion date of September 10, 2018. The contract was not set aside for any special designation. Genentech holds several key contract vehicles with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a total ceiling value of $259,393.47. The contract is a firm-fixed price delivery order with a completion date of September 20, 2017. Genentech is the prime contractor, and no major subcontractors were identified. The contract is...
This is a $112,687.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract is not designated as a set-aside. Genentech holds several key contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule with the Department of Veterans Affairs for pharmaceutical products, and a...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....
This is a delivery order under a Federal Supply Schedule contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $8,434,278.00 and a period of performance ending on September 20, 2017. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal agencies,...
This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain, a component of the Department of Defense, to Genentech USA, Inc. The contract has a ceiling value of $353,101.26 and is for the delivery of oseltamivir phosphate, an antiviral medication. The contract was awarded under a larger federal supply schedule contract between Genentech and the Department of Veterans Affairs, valued at $4.9 billion, that enables the company to efficiently provide pharmaceuticals and...
This is a federal contract award from the Medical Supply Chain of the Department of Defense to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $149,340.18. The contract is a firm-fixed price delivery order placed under an existing vehicle, with an ultimate completion date of September 21, 2017. No set-aside designation was used. Genentech...
This is a Delivery Order (SPE2DP19F5699) awarded by the Medical Supply Chain, a component of the Defense Logistics Agency (DLA), to Genentech USA, Inc. for the supply of oseltamivir phosphate, an antiviral medication, at a Firm Fixed Price of $95,996.16. The contract has an ultimate completion date of September 3, 2020. Genentech is a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics that holds several contract vehicles with federal agencies, including a $4.9 billion...
This is a delivery order awarded to Genentech USA, Inc., a biotechnology company that develops and manufactures pharmaceuticals, by the Defense Logistics Agency Troop Support Medical. The contract is for the antiviral medication oseltamivir phosphate, with a potential value of $468,558.18 and a firm fixed price pricing type. The place of performance is Genentech's facility in South San Francisco, California. The contract does not utilize any set-asides. Genentech has extensive experience...
This $342,870.90 firm fixed-price delivery order was awarded by the Defense Logistics Agency Troop Support Medical to Genentech USA, Inc., a biotechnology company that manufactures pharmaceuticals. The contract is for the antiviral drug oseltamivir phospha and does not utilize any set-aside designation. Genentech has provided a variety of biologic medicines to government agencies through multiple federal contract vehicles, including the Pharmaceuticals and Drugs Federal Supply Schedule. This...